α_1受体阻滞剂治疗男性神经原性逼尿肌尿道外括约肌功能失调的疗效和安全性分析  

Analysis of curative effect and safety by α_1 receptor blocker in the treatment of male neurogenic detrusor external urethral sphincter dysfunction

作　　者：蒲江波[1] 朱文杰[1] 李雪梅[1] 

机构地区：[1]南方医科大学附属深圳市妇幼保健院,518048

出　　处：《中国实用医药》2016年第21期3-5,共3页China Practical Medicine

摘　　要：目的探讨α_1受体阻滞剂治疗男性神经原性逼尿肌尿道外括约肌功能失调(NDSD)的疗效和安全性。方法 100例NDSD患者,随机分为对照组(47例)和观察组(53例),对照组给予安慰剂治疗,观察组给予α_1受体阻滞剂(盐酸坦索罗辛缓释胶囊)治疗。比较两组患者治疗前后间歇导尿(IC)例数、膀胱剩余尿量(PVR)、泌尿生殖系困扰调查的6项短表(UDI-6)、最大尿流率(Qmax)、最大尿流率时膀胱逼尿肌压力(Pdet.Qmax)、最大尿道闭合压力(MUCP)及不良反应发生情况。结果观察组治疗12周后UDI-6、PVR、IC例数、Qmax、Pdet.Qmax、MUCP均优于对照组(P<0.05)。观察组不良反应发生率(1.89%)与对照组(4.26%)对比,差异无统计学意义(P>0.05)。结论 NDSD患者采用α_1受体阻滞剂治疗,能有效改善自身机体排尿障碍,提高患者生活质量,值得临床推广。Objective To investigate curative effect and safety by α1 receptor blocker in the treatment of male neurogenic detrusor external urethral sphincter dysfunction （NDSD）. Methods A total of 100 NDSD patients were randomly divided into control group （47 cases） and observation group （53 cases）. The control group received placebo for treatment, and the observation group received α1 receptor blocker （tamsulosin hydrochloride sustained release capsules） for treatment. Comparison was made on intermittent catheterization （IC） cases, post-void residual volume （PVR）, urogenital system distress investigation-6 short form （UDI-6）, maximum flow rate （Qmax）, bladder detrusor pressure at maximum flow rate （Pdet.Qmax）, maximum urethral closure pressure （MUCP） and adverse reactions between the two groups. Results The observation group had all better UDI-6, PVR, IC cases, Qmax, Pdet.Qmax and MUCP after 12 weeks of treatment than the control group （P〈0.05）. There was no statistically significant difference of incidence of adverse reactions between the observation group （1.89%） and the control group （4.26%） （P〉0.05）. Conclusion Implement of α1 receptor blocker treating NDSD patients shows effective improvement of urination disorder and quality of life in patients. This method is worth clinical promotion.

关 键 词：男性神经原性逼尿肌尿道外括约肌功能失调 Α1受体阻滞剂 安全性 

分 类 号：R695[医药卫生—泌尿科学]